Bank Of America Lowers Price Target On Amylin To $15

According to Bank of America, Amylin Pharmaceuticals AMLN price target is lowered to $15. Bank of America said that AMLN/Takeda announced the discontinuation of their phase 2 obesity treatment candidate metreleptin/pramlintide (MP) following a pipeline review. “We assumed low probability of approval for the drug and have removed estimates, lowering our PO by $1 to $15.” Amylin Pharmaceuticals closed on Friday at $10.60.